As everybody knows, the CARTITIDE-1 study was a study using a novel CAR T-cell therapy, targeting BCMA in relapsed and refractory myeloma. This was a heavily pre-treated population. They had three or more prior lines of therapy and they received this therapy independent of any maintenance-based therapy. They did get bridging chemotherapy that included cyclophosphamide and fludarabine. So cyclophosphamide, fludarabine, and then infusion of CAR-T cells and then we followed them for response as well as for quality of life afterwards...
As everybody knows, the CARTITIDE-1 study was a study using a novel CAR T-cell therapy, targeting BCMA in relapsed and refractory myeloma. This was a heavily pre-treated population. They had three or more prior lines of therapy and they received this therapy independent of any maintenance-based therapy. They did get bridging chemotherapy that included cyclophosphamide and fludarabine. So cyclophosphamide, fludarabine, and then infusion of CAR-T cells and then we followed them for response as well as for quality of life afterwards.
At ASH of this year, we presented, and it was presented by Deepu Madduri, an overall response rate of 97%, which is pretty amazing. And then a PFS that was still above 70% at 12 months post CAR T-cell therapy. So this therapy is likely going to have a PFS that is certainly longer than any other CAR T-cell therapy in multiple myeloma, and we’re all really anxiously awaiting the data to see what the actual PFS will be. But really a potent therapeutic for these patients, and again, these are very heavily pre-treated patients.